Personalis PSNL
Personalis FY 2022: revenue $65.0M, down 24%; diluted EPS −$2.48
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-004139
- Document
- 10-K
Key figures from this report
These are the numbers Personalis reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$65.0M−24% from $85.5M in FY 202110-K income statement, on EDGAR
- Net income−$113.3MAgainst −$65.2M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$2.48Against −$1.49 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$89.1M−16% from $105.6M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$70.2MAgainst −$70.8M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.
- Castle Biosciences CSTL public float $576M, Jun 30, 2025
- Celcuity CELC public float $457M, Jun 30, 2025
- Fortrea Holdings FTRE public float $448M, Jun 30, 2025
- CareDx CDNA public float $1.0B, Jun 30, 2025
- Fulgent Genetics FLGT public float $284M, Jun 30, 2025
